MDS Clinical Trial
— CARTOGENOfficial title:
Optical Genome Mapping in Hematological Malignancies
Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer
Status | Recruiting |
Enrollment | 200 |
Est. completion date | September 2026 |
Est. primary completion date | September 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Minor/Major Patients - Patients with suspected hemopathies for whom we receive a sample for diagnosis in the chromosomal genetics laboratory or for whom a diagnosis of hemopathy has already been made. - No objection made or consent given Exclusion Criteria: - Patients under judicial protection (guardianship, curatorship, ...), - Refusal to participate |
Country | Name | City | State |
---|---|---|---|
France | CHRU de Brest | Brest | |
France | CH Morlaix, service d'hémato clinique | Morlaix | |
France | CHIC, service d'hémato clinique | Quimper | |
France | CH St Brieuc, service d'hémato clinique | Saint-Brieuc |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Brest |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer | identification of anomalies by mapping identical to those identified by combining conventional cytogenetics and FISH. | 2021-2026 | |
Secondary | identification of new chromosomal abnormalities of clinical relevance. | 2021-2026 | ||
Secondary | identification of new chromosomal anomalies involved in oncogenic pathways | 2021-2026 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04623944 -
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
|
Phase 1 | |
Recruiting |
NCT03680677 -
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
|
||
Not yet recruiting |
NCT04110925 -
Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia
|
N/A | |
Terminated |
NCT04638309 -
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
|
Phase 1 | |
Completed |
NCT03466320 -
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03138395 -
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML
|
N/A | |
Completed |
NCT04443751 -
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 1 | |
Completed |
NCT02103478 -
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
|
Phase 1/Phase 2 | |
Completed |
NCT00863148 -
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
Completed |
NCT00761449 -
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5
|
Phase 2 | |
Completed |
NCT00692926 -
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells
|
Phase 1 | |
Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A | |
Completed |
NCT02214407 -
Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML
|
Phase 3 | |
Recruiting |
NCT05582902 -
Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients
|
||
Not yet recruiting |
NCT05024877 -
Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia
|
Phase 2/Phase 3 | |
Completed |
NCT00321711 -
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents
|
Phase 2 | |
Recruiting |
NCT06156579 -
Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML
|
Phase 2 | |
Recruiting |
NCT05226455 -
Venetoclax in Patients With MDS or AML in Relapse After AHSCT
|
Phase 1/Phase 2 | |
Completed |
NCT01690507 -
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML)
|
Phase 1/Phase 2 | |
Completed |
NCT01241500 -
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
|
Phase 3 |